{"id":696798,"date":"2026-05-27T00:55:07","date_gmt":"2026-05-27T00:55:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/696798\/"},"modified":"2026-05-27T00:55:07","modified_gmt":"2026-05-27T00:55:07","slug":"3-asx-200-shares-id-buy-for-the-future-of-healthcare","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/696798\/","title":{"rendered":"3 ASX 200 shares I\u2019d buy for the future of healthcare"},"content":{"rendered":"

Healthcare<\/a> is one of my favourite long-term investment themes.<\/p>\n

The world is ageing, medical technology keeps improving, and patients are demanding better diagnosis, treatment, and care. That does not mean every healthcare share will do well, but I think the sector could produce some excellent long-term winners.<\/p>\n

Three ASX 200 healthcare shares I would buy for the future are named in this article. <\/p>\n

\"A<\/p>\n

Image source: Getty Images<\/p>\n

ResMed is one of the ASX 200 healthcare shares I rate most highly. <\/p>\n

The company is a global leader in sleep health, with products that help treat sleep apnoea and other respiratory conditions. I like the business model because it combines devices with recurring revenue<\/a> from masks, accessories, and software.<\/p>\n

That recurring element is important. A patient does not just buy a device once and disappear forever. They often need replacement masks, ongoing support, connected data, and better tools to manage therapy. <\/p>\n

I also think the long-term market remains underpenetrated. Many people with sleep apnoea remain undiagnosed, and awareness of the condition can still improve. <\/p>\n

There has been plenty of debate about GLP-1 weight loss drugs and what they mean for sleep apnoea treatment. I see them as more of an awareness driver than a simple threat. If more patients engage with their health, seek diagnosis, and understand the risks of untreated sleep apnoea, ResMed could still benefit. <\/p>\n

Telix Pharmaceuticals Ltd (ASX: TLX<\/a>)<\/p>\n

Telix is a higher-risk<\/a> healthcare growth share, but I think the opportunity is compelling.<\/p>\n

The company is focused on radiopharmaceuticals, including cancer imaging and targeted treatment. This is a specialised area of healthcare with the potential to improve how certain cancers are detected and treated. <\/p>\n

What I like about Telix is that it is not simply a clinical-stage dream. It already has a commercial base, while still investing in a pipeline that could create future growth. <\/p>\n

That combination is attractive, but it also comes with risk. Clinical trials can disappoint, regulatory timelines can change, and healthcare investors can quickly lose patience when expectations are high. <\/p>\n

I would not put Telix in the same risk bucket as a mature healthcare leader like ResMed. But for investors comfortable with more volatility<\/a>, I think Telix offers exposure to one of the more interesting areas of modern cancer care. <\/p>\n

If management can keep growing the commercial business and advance the pipeline, the company could look very different in a decade. <\/p>\n

Cochlear has had a difficult period, but I still think it deserves attention from long-term investors.<\/p>\n

The company is a global leader in implantable hearing solutions. Its products can make a major difference to people with severe to profound hearing loss, and I think the long-term need is clear. <\/p>\n

Ageing populations should support demand over time. Diagnosis and treatment access can also improve, especially as hearing loss becomes more widely understood as a serious health issue rather than simply an inconvenience. <\/p>\n

Cochlear’s near-term outlook has been challenged, and confidence has weakened. But I do not think the long-term healthcare need has gone away. <\/p>\n

For patient investors, the question is whether the current pressure is temporary or structural. I lean towards the former, although recovery may take time. <\/p>\n

Foolish Takeaway <\/p>\n

Healthcare investing often requires patience.<\/p>\n

A company can have a strong long-term market and still go through periods where sentiment turns against it. That is why I like looking for businesses with real clinical need behind them, not just a fashionable story. <\/p>\n

These three ASX 200 shares carry different risks, but they all have something I want in a healthcare investment: a reason to exist that should still matter many years from now. <\/p>\n","protected":false},"excerpt":{"rendered":"Healthcare is one of my favourite long-term investment themes. The world is ageing, medical technology keeps improving, and…\n","protected":false},"author":2,"featured_media":696799,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":["post-696798","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-au","tag-australia","tag-health","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/696798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=696798"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/696798\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/696799"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=696798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=696798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=696798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}